[go: up one dir, main page]

EA201890640A1 - Рекомбинантные векторы, содержащие пептид 2а - Google Patents

Рекомбинантные векторы, содержащие пептид 2а

Info

Publication number
EA201890640A1
EA201890640A1 EA201890640A EA201890640A EA201890640A1 EA 201890640 A1 EA201890640 A1 EA 201890640A1 EA 201890640 A EA201890640 A EA 201890640A EA 201890640 A EA201890640 A EA 201890640A EA 201890640 A1 EA201890640 A1 EA 201890640A1
Authority
EA
Eurasian Patent Office
Prior art keywords
vectors containing
recombinant vectors
containing peptide
peptide
vector
Prior art date
Application number
EA201890640A
Other languages
English (en)
Inventor
Дуглас Дж. Джолли
Эми Х. Лин
Эндрю Хоуфекр
Дэниел Дж. Хоуган
Дерек Г. Остертег
Original Assignee
Токаджен Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Токаджен Инк. filed Critical Токаджен Инк.
Publication of EA201890640A1 publication Critical patent/EA201890640A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70507—CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Настоящее изобретение относится к модифицированным рекомбинантным ретровирусам, содержащим последовательность, кодирующую пептид 2А или подобный ему пептид и функционально присоединенную к гетерологичному полинуклеотиду. Настоящее изобретение также относится к клеткам и к вектору, где эти клетки экспрессируют или содержат такой вектор, а также к способам применения указанных модифицированных векторов для лечения заболеваний и расстройств.
EA201890640A 2015-09-04 2016-09-01 Рекомбинантные векторы, содержащие пептид 2а EA201890640A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562214884P 2015-09-04 2015-09-04
PCT/US2016/049947 WO2017040815A1 (en) 2015-09-04 2016-09-01 Recombinant vectors comprising 2a peptide

Publications (1)

Publication Number Publication Date
EA201890640A1 true EA201890640A1 (ru) 2018-09-28

Family

ID=58188345

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890640A EA201890640A1 (ru) 2015-09-04 2016-09-01 Рекомбинантные векторы, содержащие пептид 2а

Country Status (13)

Country Link
US (1) US11279949B2 (ru)
EP (1) EP3325633A4 (ru)
JP (1) JP2018526007A (ru)
KR (1) KR20180048743A (ru)
CN (1) CN108138201A (ru)
AU (1) AU2016317936A1 (ru)
CA (1) CA2996797A1 (ru)
EA (1) EA201890640A1 (ru)
HK (1) HK1251612A1 (ru)
IL (1) IL257819A (ru)
MX (1) MX2018002744A (ru)
PH (1) PH12018500477A1 (ru)
WO (1) WO2017040815A1 (ru)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018002744A (es) * 2015-09-04 2018-04-13 Tocagen Inc Vectores recombinantes que comprenden peptido 2a.
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
BR112020011670A2 (pt) 2017-12-15 2020-11-17 Flagship Pioneering Innovations Vi, Llc. composições compreendendo polirribonucleotídeos circulares e seus usos
CN112384627A (zh) * 2018-05-30 2021-02-19 生物医学研究所 通过利用内源激活诱导性胞嘧啶脱氨酶改造b淋巴细胞
WO2019241549A1 (en) 2018-06-15 2019-12-19 A2 Biotherapeutics, Inc. Foxp3-expressing car-t regulatory cells
CN109022374B (zh) * 2018-08-16 2021-05-14 华中农业大学 一种塞内卡谷病毒重组质粒、重组病毒及构建方法
AU2019327913A1 (en) 2018-08-29 2021-03-18 Nanjing Legend Biotech Co., Ltd. Anti-mesothelin chimeric antigen receptor (CAR) constructs and uses thereof
CN113677800A (zh) * 2018-11-13 2021-11-19 索元生物医药(美国)有限公司 包含用于结合结构域和可分泌肽的基因的重组载体
US12098212B2 (en) 2019-08-12 2024-09-24 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells
KR20220074917A (ko) 2019-09-30 2022-06-03 길리애드 사이언시즈, 인코포레이티드 Hbv 백신 및 hbv를 치료하는 방법
TW202128775A (zh) 2019-10-16 2021-08-01 英商阿法克塔生命科學有限公司 PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分
US20230304031A1 (en) * 2020-05-11 2023-09-28 Abintus Bio, Inc. Vectors and methods for in vivo transduction
EP4149538A1 (en) * 2020-05-11 2023-03-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
US20230330227A1 (en) 2020-08-13 2023-10-19 A2 Biotherapeutics, Inc. Gene fusions for control of genetically modified cells
KR102424707B1 (ko) * 2020-10-12 2022-07-25 전북대학교산학협력단 표적단백질발현을 증가시킨 진핵세포질 내 다중항원발현용 재조합벡터 및 진핵세포 내 벡터전달시스템용 살모넬라 티피뮤리움의 조합 조성물
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
EP4413038A1 (en) 2021-10-07 2024-08-14 Avacta Life Sciences Limited Pd-l1 binding affimers
EP4412711A1 (en) 2021-10-07 2024-08-14 Avacta Life Sciences Limited Serum half-life extended pd-l1 binding polypeptides
JP2024540002A (ja) * 2021-10-25 2024-10-31 ジェンビーボ・インコーポレイテッド 治療剤送達のための組成物および方法
CN113999873B (zh) * 2021-12-31 2022-05-20 北京市疾病预防控制中心 一种基因修饰的非人动物的构建方法及其应用
US20250163454A1 (en) * 2022-02-09 2025-05-22 The Regents Of The University Of California In vitro and in vivo protein translation via in situ circularized rnas
CN114478713B (zh) * 2022-02-21 2023-03-28 江苏蒙彼利生物科技有限公司 一种cmv包膜蛋白包装慢病毒载体及其应用
EP4514389A1 (en) 2022-04-29 2025-03-05 Purinomia Biotech, Inc. Methods and compositions for treating eosinophil driven diseases and disorders
US20260028602A1 (en) * 2022-08-09 2026-01-29 Asimov Inc. Split recombinases having inducible recombinase activity
CN116286993A (zh) * 2023-03-01 2023-06-23 武汉科技大学 一种HIV-tat致神经损伤模型的建立方法及其用途
WO2025029840A1 (en) 2023-07-31 2025-02-06 Tune Therapeutics, Inc. Compositions and methods for multiplexed activation and repression of t cell gene expression
WO2025038668A1 (en) 2023-08-14 2025-02-20 Voro Therapeutics, Inc. Therapeutic binding agents that conditionally promote myeloid cell activity against target cells and uses thereof
CN117264911A (zh) * 2023-09-13 2023-12-22 中国科学院深圳先进技术研究院 一种高灵敏表达红色荧光蛋白的重组伪狂犬病毒及其制备方法和应用
WO2025239464A1 (ko) * 2024-05-14 2025-11-20 대한뉴팜(주) 신규한 펩타이드 및 이의 항바이러스 용도

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69420033T2 (de) 1993-04-06 1999-12-23 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Bethesda Gibbon leukemia virus retrovirale vektoren
US20030157070A1 (en) 1994-12-30 2003-08-21 Jolly Douglas J. High efficiency ex vivo transduction of cells by high titer recombinant retroviral preparations
US6117681A (en) 1995-03-29 2000-09-12 Bavarian Nordic Research Inst. A/S Pseudotyped retroviral particles
US20030026789A1 (en) 1995-05-03 2003-02-06 Richard J. Gregory Gene therapy using replication competent targeted adenoviral vectors
US5912167A (en) * 1995-06-06 1999-06-15 Wisconsin Alumni Research Foundation Autocatalytic cleavage site and use thereof in a protein expression vector
AU1334999A (en) 1997-10-20 1999-05-10 Universita Degli Studi Di Padova A packaging cell line producing siv-pseudotyped mlv
FR2773561A1 (fr) 1998-01-15 1999-07-16 Centre Nat Rech Scient Utilisation d'une sequence riche en proline pour augmenter le caractere fusogenique d'enveloppes de retrovirus
US6451304B1 (en) 1998-03-09 2002-09-17 The Regents Of The University Of California Method for retrovirus vector production by separated gag and pol expression
EP1076714A1 (en) 1998-04-29 2001-02-21 Oklahoma Medical Research Foundation Construction of retroviral producer cells from adenoviral and retroviral vectors
US7001733B1 (en) 1998-05-12 2006-02-21 Rigel Pharmaceuticals, Inc. Methods and compositions for screening for modulations of IgE synthesis, secretion and switch rearrangement
WO1999060110A2 (en) 1998-05-20 1999-11-25 The University Of Tennessee Research Corporation Stable envelope proteins for retroviral, viral and liposome vectors and use in gene and drug therapy
US6264940B1 (en) 1998-08-05 2001-07-24 The Research Foundation Of State University Of New York Recombinant poliovirus for the treatment of cancer
US6899871B2 (en) 1998-10-01 2005-05-31 University Of Southern California Gene delivery system and methods of use
AU1441900A (en) 1998-10-01 2000-04-17 University Of Southern California Gene delivery system and methods of use
US6576463B1 (en) 1999-01-15 2003-06-10 The Regents Of The University Of California Hybrid vectors for gene therapy
WO2000066758A1 (en) 1999-04-29 2000-11-09 Aarhus University Expression of heterologous genes from an ires translational cassette in retroviral vectors
GB2368846B (en) 1999-07-08 2004-08-25 Univ California Isolated Jaagsiekte retroviruses (JSRV), gene delivery vectors, and methods of use
US8163893B2 (en) 2006-02-15 2012-04-24 The Regents Of The University Of Caifornia Pseudotyped retroviral vectors and methods of use thereof
WO2001040488A1 (en) 1999-11-30 2001-06-07 Novartis Ag Increased transgene expression in retroviral vectors having scaffold attachment region
US6692736B2 (en) 2000-03-24 2004-02-17 Cell Genesys, Inc. Cell-specific adenovirus vectors comprising an internal ribosome entry site
AU2001292711A1 (en) 2000-09-18 2002-03-26 Genetic Therapy, Inc. Stress resistant retroviruses
US20030003565A1 (en) 2000-11-27 2003-01-02 Dubensky Thomas W. Functional lentiviral vector from an MLV-based backbone
US7226779B2 (en) 2001-01-30 2007-06-05 The United States Of America As Represented By The Department Of Health And Human Services Hybrid adenoviral vector
DE10111433A1 (de) 2001-03-09 2002-09-19 Bundesrepublik Deutschland Let Replikationskompetente molekulare Klone von porcinem endogenem Retrovirus der Klasse A und Klasse B,abgeleitet von Schweine- und humanen Zellen
JP2002335965A (ja) 2001-05-14 2002-11-26 Japan Science & Technology Corp 細胞特異的発現複製ベクター
DE10143237A1 (de) 2001-09-04 2003-03-20 Icon Genetics Ag Herstellung künstlicher interner ribosomaler Eingangsstellenelemente (Ires-Elemente)
EP1424895B1 (en) 2001-09-13 2009-08-12 California Institute Of Technology Method for expression of small antiviral rna molecules within a cell
FR2832424B1 (fr) 2001-11-20 2004-09-24 Genethon Iii Plasmide chimere comprenant un genome retroviral replicatif et utilisations
EP1470233A1 (en) 2002-02-01 2004-10-27 Transgene S.A. Adenoviral vectors for modulating the cellular activities associated with pods
US20030180808A1 (en) * 2002-02-28 2003-09-25 Georges Natsoulis Drug signatures
US20060147420A1 (en) 2004-03-10 2006-07-06 Juan Fueyo Oncolytic adenovirus armed with therapeutic genes
AU2003251931B2 (en) 2002-07-17 2008-03-06 Bristol-Myers Squibb Company Transgenic non-human mammals expressing a reporter nucleic acid under the regulation of androgen response elements
US20080227736A1 (en) 2004-06-03 2008-09-18 Regents Of The University Of California, Targeting Pseudotyped Retroviral Vectors
US20070003522A1 (en) 2004-07-08 2007-01-04 Albritton Lorraine M Methods and compositions for improved retroviral gene and drug delivery
JP2008518902A (ja) 2004-11-04 2008-06-05 ファイザー・プロダクツ・インク 乳癌のためのｃｔｌａ４抗体とアロマターゼ阻害剤の併用治療
EP1817422A2 (en) 2004-11-24 2007-08-15 Nanovector Limited Viral vectors
WO2006127980A2 (en) 2005-05-25 2006-11-30 The Regents Of The University Of California Optimized core promoters and uses therefor
WO2007041350A2 (en) 2005-10-01 2007-04-12 Charles Stout Regulatable fusion promoters
WO2007044483A2 (en) 2005-10-07 2007-04-19 President And Fellows Of Harvard College Attenuated vaccines for non-segmented negative sense rna viruses
EP1795596A1 (en) 2005-12-08 2007-06-13 Ganymed Pharmaceuticals AG Composition and methods for therapy and diagnosis of cancer
WO2007107156A2 (en) 2006-03-17 2007-09-27 Aarhus Universitet Chimeric viral envelopes
EP2049659A1 (de) * 2006-07-24 2009-04-22 AB Enzymes GmbH Vektorkonstrukte und verfahren zur expression und sekretion von polypeptiden in filamentösen pilzen unter verwendung einer selbstprozessierenden 2a-spaltstelle
WO2008151633A2 (en) 2007-06-15 2008-12-18 Skau Aps Vectors for vaccines against lentivirus infections
US20110136730A1 (en) * 2008-04-18 2011-06-09 John Fuller Atkins "Method for screening compounds comprising the use of picornavirus protease 2A"
AU2009257219B2 (en) * 2008-06-13 2015-01-29 Whitehead Institute For Biomedical Research Programming and reprogramming of cells
CA2724740C (en) 2008-06-30 2017-02-21 Tocagen Inc. Formulations of 5-fluorocytosine and uses thereof
US8829173B2 (en) * 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
EP2346995B1 (en) * 2008-09-26 2018-11-07 Tocagen Inc. Gene therapy vectors and cytosine deaminases
CN101367749B (zh) * 2008-09-28 2013-04-24 中国医学科学院医药生物技术研究所 一组胺基苯酰衍生物及其制备方法和应用
CA2743669C (en) * 2008-11-24 2018-10-16 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) High affinity t cell receptor and use thereof
CN101532030A (zh) * 2009-04-21 2009-09-16 中国科学院广州生物医药与健康研究院 一种na片段携带外源基因的重组流感病毒载体及其制备方法和应用
WO2010148203A2 (en) * 2009-06-17 2010-12-23 Tocagen Inc. Producer cells for replication competent retroviral vectors
CN101709084B (zh) * 2009-11-26 2012-07-04 中国科学院广州生物医药与健康研究院 优化的串连细胞因子及其在诱导多能性干细胞中的应用
US9187762B2 (en) 2010-08-13 2015-11-17 Pioneer Hi-Bred International, Inc. Compositions and methods comprising sequences having hydroxyphenylpyruvate dioxygenase (HPPD) activity
JP6419706B2 (ja) * 2012-10-25 2018-11-07 トカジェン インコーポレーテッド ミニプロモーターカセットを含むレトロウイルスベクター
US20150086509A1 (en) * 2013-09-25 2015-03-26 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating cancer using interferon and mapk pathway inhibitor
GB201405845D0 (en) * 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
GB201507104D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic acid construct
CN104946686A (zh) * 2015-05-29 2015-09-30 广东大华农动物保健品股份有限公司 用于表达猪流行性腹泻蛋白中m蛋白、n蛋白和s1蛋白的重组质粒及其构建方法和应用
MX2018002744A (es) * 2015-09-04 2018-04-13 Tocagen Inc Vectores recombinantes que comprenden peptido 2a.
GB201812474D0 (en) * 2018-07-31 2018-09-12 Autolus Ltd Nucleic acid construct
CN110564772B (zh) * 2019-04-03 2022-07-05 安泰吉（北京）生物技术有限公司 改造宿主细胞基因组的方法及其用途

Also Published As

Publication number Publication date
MX2018002744A (es) 2018-04-13
EP3325633A1 (en) 2018-05-30
WO2017040815A1 (en) 2017-03-09
IL257819A (en) 2018-04-30
HK1251612A1 (zh) 2019-02-01
US11279949B2 (en) 2022-03-22
CN108138201A (zh) 2018-06-08
US20180251786A1 (en) 2018-09-06
CA2996797A1 (en) 2017-03-09
KR20180048743A (ko) 2018-05-10
AU2016317936A1 (en) 2018-03-08
EP3325633A4 (en) 2019-01-16
JP2018526007A (ja) 2018-09-13
PH12018500477A1 (en) 2018-09-10

Similar Documents

Publication Publication Date Title
EA201890640A1 (ru) Рекомбинантные векторы, содержащие пептид 2а
EA201791426A1 (ru) Полипептид и иммуномодуляция
EA202091710A1 (ru) Антитела против cd73 и способы их применения
PH12019500709A1 (en) Anti-lag-3 antibodies and methods of use thereof
EA201991383A1 (ru) Антитела против ctla-4 и способы их применения
EA201991720A1 (ru) Антитела к альфа-синуклеину и их применения
EA201891137A1 (ru) Вирусные векторы, кодирующие рекомбинантные варианты fviii с повышенной экспрессией для генной терапии гемофилии a
EA202091995A1 (ru) Композиции и способы лечения не связанного с возрастом нарушения слуха у субъекта-человека
MX2018009375A (es) Genes del factor viii optimizados.
EA201792573A1 (ru) Триспецифические связанные белки и способы их применения
EA201990912A1 (ru) Анти-lag-3 антитела и их композиции
EA201791775A1 (ru) Цистеиновая протеаза
EA201892225A1 (ru) АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
EA201790413A1 (ru) Антитела против tigit
EA201892561A1 (ru) Гибридные белки gdf15 и их применение
EA201891732A1 (ru) Биспецифичные связывающие белки для pd-l1 и kdr
EA201792651A1 (ru) Аденовирусные полинуклеотиды и полипептиды
CY1123031T1 (el) Ρυθμιστες της δραστικοτητας του συμπληρωματος
EA201892006A1 (ru) Aav-опосредованная экспрессия с использованием синтетического промотора и энхансера
EA201791768A1 (ru) Иммуномодулирующие агенты
EA201691541A1 (ru) Новые анти-baff антитела
EA201890861A1 (ru) Композиции, содержащие лентивирусные векторы, экспрессирующие il-12, и способы их применения
MX382218B (es) Variantes de lipasa y polinucleotidos que las codifican.
EA201890351A1 (ru) Рекомбинантный orf-вирусный вектор
EA201992206A1 (ru) Моноклональное антитело к pd-l1